Ohio State University Hospitals

Ohio State University Hospitals was paid $197.87M by Medicaid between Jan 2018 and Dec 2024, across 886 billing codes. Its largest line is 99211, Office or other outpatient visit for the evaluation and management of an established patient, minimal severity — 8.4% of everything it billed.

33Billing provider infoOHIO STATE UNIVERSITY HOSPITALS
COLUMBUS, OH 43210

33aNPI1447359997assigned 09/21/2006

33bProvider typeGeneral Acute Care Hospital

28Total paid$197.87M

24GClaims4,103,101

24DCodes billed886

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other General Acute Care Hospital providers in Ohio

Rank by total paid#4 of 101

Median peer was paid$22.32M

This provider vs. median8.9×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	250,364	$10.12M
2019	231,497	$9.83M
2020	173,201	$12.19M
2021	209,920	$13.74M
2022	326,854	$16.25M
2023	1,586,769	$79.05M
2024incomplete	1,324,496	$56.67M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	8.4%	153,205	133,793	$16.61M
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	5.2%	116,174	42,583	$10.29M
99285	Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life	5.1%	66,274	57,635	$10.02M
J1745	Injection, infliximab, excludes biosimilar, 10 mg	4.0%	6,141	3,203	$7.85M
99284	Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity	3.5%	46,799	42,536	$7.02M
99283	Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity	3.1%	41,951	38,768	$6.14M
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	2.8%	57,297	51,118	$5.62M
J2350	Injection, ocrelizumab, 1 mg	1.8%	135	107	$3.62M
J1459	Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg	1.8%	2,582	684	$3.47M
J0585	Injection, onabotulinumtoxina, 1 unit	1.7%	4,520	3,254	$3.42M
96361	Intravenous infusion, hydration; each additional hour	1.7%	9,508	7,115	$3.27M
76816	Ultrasound, pregnant uterus, real time with image documentation, follow-up	1.6%	21,422	19,265	$3.11M

874 more codes

59025	Fetal non-stress test	1.5%	15,370	$3.01M
G0378	Hospital observation service, per hour	1.5%	36,378	$2.89M
J0741	Injection, cabotegravir and rilpivirine, 2mg/3mg	1.3%	457	$2.56M
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	1.2%	12,827	$2.45M
J3380	Injection, vedolizumab, intravenous, 1 mg	1.2%	447	$2.41M
74177	Computed tomography, abdomen and pelvis; with contrast material	1.2%	8,593	$2.31M
70450	Computed tomography, head or brain; without contrast material	1.0%	7,120	$2.06M
99282	Emergency department visit for the evaluation and management, low to moderate severity	1.0%	14,820	$2.01M
66984	Extracapsular cataract removal with insertion of intraocular lens prosthesis	<1%	2,197	$1.81M
J0178	Injection, aflibercept, 1 mg	<1%	1,602	$1.77M
81513		<1%	10,548	$1.70M
96415		<1%	4,478	$1.66M
90853	Group psychotherapy (other than of a multiple-family group)	<1%	14,230	$1.65M
95810	Polysomnography; sleep staging with 4 or more additional parameters	<1%	2,079	$1.62M
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	4,806	$1.59M
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	<1%	8,635	$1.55M
67028	Intravitreal injection of a pharmacologic agent	<1%	7,796	$1.53M
99213	Doctor's office visit, returning patient (routine)	<1%	14,392	$1.48M
J2357	Injection, omalizumab, 5 mg	<1%	1,186	$1.45M
76811	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed	<1%	9,071	$1.42M
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	<1%	2,666	$1.33M
80051		<1%	121,315	$1.20M
71275	Computed tomographic angiography, chest, with contrast material	<1%	4,029	$1.17M
70553	Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences	<1%	3,896	$1.14M
99281	Emergency department visit for the evaluation and management, self-limited or minor	<1%	8,301	$1.04M
76817	Ultrasound, pregnant uterus, real time with image documentation, transvaginal	<1%	13,246	$1.04M
95886		<1%	3,691	$1.04M
92134		<1%	20,088	$1.03M
64615		<1%	3,266	$1.01M
45380	Colonoscopy, flexible; with biopsy, single or multiple	<1%	1,829	$970K
80053	Comprehensive metabolic panel	<1%	46,934	$962K
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	<1%	8,283	$887K
45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s)	<1%	1,343	$842K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	<1%	735	$837K
93798		<1%	12,475	$705K
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	5,934	$698K
93306	Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete	<1%	2,628	$688K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	33,206	$671K
97542		<1%	16,696	$664K
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete	<1%	3,069	$663K
62323		<1%	1,258	$644K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	166,938	$634K
84443	Thyroid stimulating hormone (TSH)	<1%	32,462	$630K
73030		<1%	9,633	$626K
82565		<1%	131,434	$623K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	25,958	$616K
76705	Ultrasound, abdominal, real time with image documentation; limited	<1%	5,456	$611K
73721	Magnetic resonance imaging, any joint of lower extremity; without contrast material	<1%	2,255	$609K
90651		<1%	1,928	$595K
97112	Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination	<1%	17,167	$591K
H0015	Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education	<1%	4,883	$590K
73564		<1%	7,092	$590K
93458		<1%	515	$583K
71046	Radiologic examination, chest; 2 views	<1%	24,647	$561K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	33,198	$554K
97530	Therapeutic activities, direct patient contact, each 15 minutes	<1%	14,847	$549K
19318		<1%	102	$529K
71260	Computed tomography, thorax, diagnostic; with contrast material	<1%	2,064	$520K
97140	Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage)	<1%	21,964	$500K
92250		<1%	7,367	$500K
73630		<1%	8,246	$495K
95885		<1%	1,614	$494K
74176	Computed tomography, abdomen and pelvis; without contrast material	<1%	1,652	$488K
73502		<1%	7,503	$486K
83036	Hemoglobin; glycosylated (A1C)	<1%	34,741	$484K
80076		<1%	42,787	$481K
43235		<1%	1,001	$479K
80061	Lipid panel	<1%	29,533	$475K
49083		<1%	1,099	$472K
95811		<1%	582	$472K
87481		<1%	22,138	$471K
G0463	Hospital outpatient clinic visit for assessment and management of a patient	<1%	38,622	$463K
86850		<1%	18,187	$455K
Q5103	Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg	<1%	994	$452K
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	<1%	2,740	$444K
J0485	Injection, belatacept, 1 mg	<1%	1,058	$442K
J9312	Injection, rituximab, 10 mg	<1%	97	$441K
J7307	Etonogestrel (contraceptive) implant system, including implant and supplies	<1%	379	$439K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	20,477	$439K
J3032	Injection, eptinezumab-jjmr, 1 mg	<1%	161	$433K
74183		<1%	1,604	$433K
99215	Doctor's office visit, returning patient (complex)	<1%	3,974	$424K
90870		<1%	1,271	$421K
97162		<1%	8,396	$419K
70496		<1%	1,410	$417K
J1439	Injection, ferric carboxymaltose, 1 mg	<1%	523	$415K
64415		<1%	1,208	$409K
97161		<1%	7,319	$396K
70491		<1%	1,311	$388K
92083		<1%	4,941	$383K
72148	Magnetic resonance imaging, lumbar spine; without contrast material	<1%	1,988	$381K
97113		<1%	3,962	$368K
H0012	Alcohol and/or drug services; sub-acute detoxification (residential addiction program outpatient)	<1%	1,158	$365K
36415	Collection of venous blood by venipuncture	<1%	177,317	$359K
99214	Doctor's office visit, returning patient (more involved)	<1%	3,390	$353K
99202	Office or other outpatient visit for the evaluation and management of a new patient, straightforward	<1%	2,976	$335K
73221		<1%	1,225	$325K
J3490	Unclassified drugs	<1%	23,080	$318K
71250		<1%	2,563	$317K
73610		<1%	5,286	$317K
86780		<1%	20,961	$314K
70551	Magnetic resonance imaging, brain; without contrast material	<1%	1,636	$312K
84520		<1%	125,308	$311K
64493		<1%	446	$309K
94375		<1%	2,829	$305K
85027		<1%	49,530	$304K
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	<1%	1,093	$298K
72197		<1%	921	$297K
78452	Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress	<1%	682	$295K
72141		<1%	1,421	$290K
27130		<1%	66	$290K
76805	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation	<1%	1,904	$284K
86803		<1%	16,487	$267K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	21,573	$263K
J1050	Injection, medroxyprogesterone acetate, 1 mg	<1%	2,924	$259K
86900		<1%	19,161	$259K
82728		<1%	15,190	$258K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	13,287	$252K
84439		<1%	10,825	$240K
90837	Psychotherapy session, about an hour	<1%	2,098	$237K
66982		<1%	323	$235K
97016		<1%	5,255	$228K
92133		<1%	5,258	$227K
97535	Self-care/home management training, each 15 minutes	<1%	6,641	$224K
76815	Ultrasound, pregnant uterus, real time with image documentation, limited	<1%	3,572	$217K
11042	Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm	<1%	1,252	$214K
41899	Unlisted procedure, dentoalveolar structures	<1%	284	$210K
76770		<1%	1,249	$210K
82607		<1%	10,547	$206K
80048	Basic metabolic panel (calcium, ionized)	<1%	21,991	$206K
C9257	Injection, bevacizumab, 0.25 mg	<1%	3,764	$202K
94726		<1%	3,269	$200K
87088		<1%	19,104	$198K
45378	Colonoscopy, flexible; diagnostic, including collection of specimen(s)	<1%	308	$198K
93308		<1%	711	$190K
94618		<1%	1,920	$190K
97163		<1%	3,850	$189K
J0897	Injection, denosumab, 1 mg	<1%	285	$187K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	8,293	$184K
85610		<1%	40,919	$183K
29848		<1%	115	$178K
P9016	Red blood cells, leukocytes reduced, each unit	<1%	706	$177K
64721		<1%	243	$175K
72110		<1%	4,432	$174K
97165		<1%	2,354	$174K
87340		<1%	13,409	$171K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	10,129	$169K
77063	Screening digital breast tomosynthesis, bilateral	<1%	2,958	$164K
G0121	Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk	<1%	247	$163K
76536		<1%	1,271	$163K
88341		<1%	3,840	$161K
83735		<1%	67,520	$159K
72158		<1%	898	$158K
86140		<1%	15,057	$157K
36430		<1%	950	$157K
82947		<1%	96,058	$156K
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	35,978	$155K
94729		<1%	3,048	$153K
87505		<1%	1,352	$153K
G0260	Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography	<1%	482	$152K
97116		<1%	5,466	$152K
76820		<1%	2,231	$150K
94010		<1%	1,756	$149K
93296		<1%	6,042	$145K
64450		<1%	1,035	$145K
74174		<1%	1,681	$143K
77073		<1%	1,748	$142K
86706		<1%	8,557	$141K
78264		<1%	486	$141K
75561		<1%	457	$139K
84466		<1%	14,568	$138K
J2323	Injection, natalizumab, 1 mg	<1%	19	$138K
86704		<1%	7,818	$137K
70543		<1%	391	$136K
88185		<1%	4,342	$135K
97166		<1%	2,619	$134K
99291	Critical care, evaluation and management of the critically ill patient, first 30-74 minutes	<1%	1,127	$132K
86480		<1%	4,236	$132K
G0476	Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test	<1%	4,755	$131K
27447		<1%	34	$131K
74178		<1%	468	$130K
81001		<1%	47,897	$129K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	9,411	$127K
83540		<1%	14,144	$127K
87640		<1%	3,673	$126K
86832		<1%	4,406	$125K
72156		<1%	828	$124K
73562		<1%	3,905	$124K
10060		<1%	662	$124K
P9047	Infusion, albumin (human), 25%, 50 ml	<1%	485	$123K
70487		<1%	396	$123K
73700		<1%	723	$123K
83970		<1%	6,757	$122K
75574		<1%	402	$122K
84484		<1%	38,809	$121K
72084		<1%	2,255	$118K
J7297	Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg	<1%	301	$117K
76830	Ultrasound, transvaginal	<1%	2,962	$117K
72050		<1%	1,971	$116K
93017		<1%	1,467	$116K
93971		<1%	1,367	$116K
87522	Neg quan hep c or qual rna	<1%	3,377	$115K
86901		<1%	19,155	$115K
J1750	Injection, iron dextran, 50 mg	<1%	991	$114K
93321		<1%	494	$114K
82570		<1%	14,931	$111K
90791	Psychiatric diagnostic evaluation	<1%	460	$111K
93970		<1%	730	$111K
97035		<1%	1,538	$109K
87902		<1%	581	$108K
86038		<1%	4,616	$108K
90834	Psychotherapy session, about 45 minutes	<1%	1,036	$108K
76981		<1%	748	$107K
71271		<1%	519	$106K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	15,648	$105K
88307		<1%	1,197	$103K
70486		<1%	1,322	$103K
99203	Doctor's office visit, new patient (routine)	<1%	1,025	$101K
73130		<1%	2,984	$101K
87536		<1%	2,499	$100K
86235		<1%	7,372	$98K
71045	Radiologic examination, chest; single view	<1%	13,825	$97K
76801		<1%	2,067	$97K
64405		<1%	287	$97K
93451		<1%	74	$97K
C8929	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography	<1%	434	$95K
94660		<1%	977	$95K
0202U	Oncology (prostate), multianalyte, gene expression profiling	<1%	842	$94K
87077		<1%	11,360	$91K
36224		<1%	51	$91K
80197		<1%	6,035	$87K
72125	Computed tomography, cervical spine; without contrast material	<1%	2,776	$87K
76882		<1%	755	$87K
31624		<1%	162	$87K
16020		<1%	2,000	$86K
86360		<1%	1,645	$84K
82784		<1%	9,374	$84K
77080		<1%	1,138	$83K
73120		<1%	1,043	$83K
72082		<1%	1,830	$82K
97167		<1%	2,089	$82K
52356		<1%	50	$82K
90832	Psychotherapy session, about 30 minutes	<1%	1,027	$81K
H0005	Alcohol and/or drug services; group counseling by a clinician	<1%	1,157	$80K
94060		<1%	631	$80K
93975		<1%	530	$79K
73110		<1%	1,824	$79K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	8,605	$79K
87641		<1%	3,733	$78K
20610		<1%	387	$77K
20680		<1%	90	$76K
70498		<1%	1,465	$76K
72100		<1%	2,023	$75K
91200		<1%	603	$74K
43264		<1%	93	$73K
43237		<1%	191	$73K
J0491	Injection, anifrolumab-fnia, 1 mg	<1%	18	$71K
29881		<1%	104	$70K
86003		<1%	7,188	$70K
87150		<1%	2,663	$70K
82105		<1%	4,250	$69K
73200		<1%	454	$69K
87517		<1%	1,625	$69K
74018		<1%	1,947	$68K
85652		<1%	13,637	$67K
86833		<1%	4,410	$66K
20553		<1%	378	$66K
73560		<1%	1,127	$65K
86160		<1%	5,433	$65K
82248		<1%	17,117	$65K
81370		<1%	475	$65K
95715		<1%	110	$65K
99201		<1%	652	$64K
84153		<1%	3,490	$63K
Q0222	Injection, bebtelovimab, 175 mg	<1%	68	$63K
88184		<1%	696	$63K
86364		<1%	4,471	$62K
92025		<1%	735	$62K
72146		<1%	542	$61K
J0561	Injection, penicillin g benzathine, 100,000 units	<1%	179	$61K
83880		<1%	11,367	$60K
80069		<1%	2,836	$60K
72157		<1%	610	$59K
84100		<1%	37,467	$58K
95909		<1%	407	$58K
64483		<1%	91	$58K
81329		<1%	948	$57K
73590		<1%	1,629	$57K
74220		<1%	784	$56K
84702		<1%	6,092	$56K
85730		<1%	19,073	$56K
93350		<1%	530	$55K
93976		<1%	225	$54K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	5,273	$54K
93325		<1%	593	$54K
12001		<1%	304	$53K
86762		<1%	3,929	$53K
87497		<1%	1,762	$53K
72131		<1%	1,834	$52K
92136		<1%	1,247	$52K
93299		<1%	2,068	$51K
76813		<1%	388	$51K
82043		<1%	6,378	$50K
84403		<1%	2,359	$50K
73503		<1%	596	$49K
81222		<1%	557	$48K
64635		<1%	74	$46K
77067	Screening mammography, bilateral, including computer-aided detection	<1%	3,160	$46K
72070		<1%	1,076	$45K
82310		<1%	8,697	$45K
83520		<1%	2,837	$45K
95910		<1%	495	$44K
82670		<1%	1,433	$44K
92020		<1%	745	$44K
76512		<1%	591	$44K
73080		<1%	1,136	$43K
95912		<1%	391	$42K
76819	Fetal biophysical profile; without non-stress testing	<1%	487	$42K
58300		<1%	337	$41K
43244		<1%	77	$41K
86923		<1%	1,866	$41K
64494		<1%	416	$41K
82040		<1%	4,249	$41K
G0239	Therapeutic procedures to improve respiratory function or increase strength or endurance of respiratory muscles, two or more individuals (includes monitoring)	<1%	1,257	$40K
92235		<1%	351	$39K
62328		<1%	75	$39K
84460		<1%	7,142	$38K
86708		<1%	2,412	$38K
86787		<1%	3,689	$38K
81373		<1%	264	$38K
84703		<1%	29,311	$37K
72040		<1%	935	$37K
84450		<1%	6,800	$37K
82247		<1%	3,780	$36K
00104		<1%	1,433	$36K
96367		<1%	1,069	$36K
83013		<1%	637	$36K
93922		<1%	563	$36K
73552		<1%	1,034	$36K
H2036	Alcohol and/or other drug treatment program, per diem	<1%	445	$36K
87081		<1%	3,006	$35K
97597		<1%	359	$35K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	8,425	$34K
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	<1%	171	$34K
62321		<1%	62	$34K
83516		<1%	2,067	$34K
82746		<1%	5,134	$33K
43249		<1%	100	$32K
95913		<1%	350	$32K
90715		<1%	1,582	$32K
82977		<1%	4,656	$32K
86376		<1%	1,537	$31K
86431		<1%	1,916	$31K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	1,479	$30K
97602		<1%	174	$29K
87493		<1%	916	$29K
87070		<1%	3,874	$29K
87510		<1%	4,784	$29K
97750		<1%	531	$29K
82550		<1%	3,831	$29K
72052		<1%	741	$29K
64447		<1%	210	$29K
36589		<1%	76	$28K
86147		<1%	1,209	$28K
66821		<1%	119	$27K
86334		<1%	1,563	$27K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	22,844	$27K
83721		<1%	2,778	$27K
84075		<1%	5,604	$27K
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	<1%	21,035	$27K
73140		<1%	434	$27K
01916		<1%	130	$27K
84156		<1%	7,414	$27K
G2066	Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results	<1%	1,841	$26K
83001		<1%	1,289	$26K
87529		<1%	1,353	$25K
87186		<1%	4,265	$25K
84146		<1%	1,327	$25K
84270		<1%	1,254	$25K
86200		<1%	1,394	$25K
86225		<1%	1,929	$24K
72128		<1%	1,493	$23K
83690		<1%	24,593	$23K
84550		<1%	5,179	$23K
82103		<1%	1,390	$23K
82533		<1%	994	$23K
90714		<1%	1,168	$23K
84481		<1%	1,691	$23K
93320		<1%	186	$23K
70480		<1%	119	$22K
87660		<1%	4,929	$22K
87799		<1%	1,825	$21K
90686		<1%	985	$21K
97150	Therapeutic procedure(s), group (2 or more individuals)	<1%	1,038	$21K
86870		<1%	666	$21K
M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	<1%	87	$21K
86015		<1%	1,211	$20K
84480		<1%	1,491	$20K
82077		<1%	4,682	$20K
80143		<1%	1,633	$19K
71100		<1%	617	$19K
83605		<1%	9,092	$18K
83021		<1%	1,172	$18K
85007		<1%	4,151	$18K
86341		<1%	1,104	$18K
80377		<1%	1,086	$18K
92507	Treatment of speech, language, voice, communication, and/or auditory processing disorder	<1%	334	$17K
97760		<1%	278	$17K
J1170	Injection, hydromorphone, up to 4 mg	<1%	14,697	$17K
86592		<1%	1,611	$17K
73060		<1%	646	$17K
83993		<1%	832	$17K
87480		<1%	4,872	$17K
95816		<1%	92	$17K
90935	Hemodialysis procedure with single evaluation by a physician	<1%	56	$17K
80320		<1%	685	$16K
57452		<1%	59	$16K
95911		<1%	206	$16K
72114		<1%	900	$16K
78306		<1%	81	$16K
J7999	Compounded drug, not otherwise classified	<1%	3,517	$15K
82803		<1%	5,939	$15K
82785		<1%	569	$15K
74022		<1%	272	$15K
76870		<1%	551	$15K
83876		<1%	719	$15K
83655		<1%	630	$15K
75635		<1%	61	$14K
80329		<1%	603	$14K
72202		<1%	329	$14K
70544		<1%	79	$14K
82088		<1%	448	$14K
86381		<1%	870	$14K
85018		<1%	6,435	$14K
82627		<1%	532	$14K
81025		<1%	5,898	$14K
72190		<1%	219	$14K
82951		<1%	525	$14K
87040		<1%	5,726	$14K
82525		<1%	796	$14K
92523		<1%	321	$13K
94625		<1%	451	$13K
84630		<1%	1,184	$13K
84165		<1%	1,798	$13K
96375	Therapeutic injection; each additional sequential IV push	<1%	16,617	$13K
87205		<1%	3,451	$13K
C1776	Joint device (implantable)	<1%	662	$13K
73522		<1%	382	$13K
84425		<1%	1,833	$13K
85014		<1%	2,935	$13K
84590		<1%	1,875	$13K
12002		<1%	71	$13K
80074		<1%	1,115	$13K
83921		<1%	1,472	$12K
82465		<1%	1,277	$12K
73090		<1%	653	$12K
73720		<1%	51	$12K
86644		<1%	1,056	$12K
97012		<1%	280	$12K
83883		<1%	314	$12K
88112		<1%	475	$12K
84207		<1%	880	$12K
96376		<1%	4,506	$12K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	2,123	$11K
88360		<1%	212	$11K
74160		<1%	62	$11K
30140		<1%	46	$11K
82330		<1%	2,232	$11K
86696		<1%	1,782	$11K
86665		<1%	1,267	$11K
83615		<1%	3,026	$11K
86593		<1%	862	$11K
93298		<1%	525	$11K
86695		<1%	1,762	$11K
11982		<1%	45	$11K
74230		<1%	91	$11K
83002		<1%	614	$11K
J1650	Injection, enoxaparin sodium, 10 mg	<1%	10,016	$10K
87015		<1%	1,940	$10K
00731		<1%	3,779	$10K
83519		<1%	968	$10K
95700		<1%	89	$10K
29581		<1%	62	$10K
86036		<1%	832	$10K
36600		<1%	513	$10K
86146		<1%	1,020	$10K
82390		<1%	799	$10K
72170		<1%	1,108	$10K
83521		<1%	1,399	$10K
84244		<1%	413	$9K
86255		<1%	1,209	$9K
67228		<1%	41	$9K
84134		<1%	1,033	$9K
73000		<1%	178	$9K
85049		<1%	2,533	$9K
72200		<1%	187	$9K
86707		<1%	406	$9K
87154		<1%	107	$9K
84681		<1%	776	$9K
86880		<1%	674	$9K
80323		<1%	301	$9K
99204	Doctor's office visit, new patient (more involved)	<1%	135	$8K
51798		<1%	713	$8K
92285		<1%	193	$8K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	<1%	122	$8K
81379		<1%	64	$8K
82164		<1%	503	$8K
88142		<1%	528	$8K
93303	Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study	<1%	27	$8K
83525		<1%	394	$8K
92611		<1%	85	$7K
86800		<1%	374	$7K
82952		<1%	469	$7K
80164		<1%	599	$7K
86705		<1%	364	$7K
58301		<1%	62	$7K
81003		<1%	7,041	$7K
85379		<1%	2,763	$7K
84144		<1%	215	$7K
82140		<1%	1,037	$7K
86709		<1%	738	$7K
62370		<1%	129	$6K
84132		<1%	3,199	$6K
86920		<1%	418	$6K
82104		<1%	641	$6K
86765		<1%	491	$6K
83010		<1%	637	$6K
73020		<1%	83	$6K
96368		<1%	319	$6K
94799		<1%	131	$6K
G0297	Low dose ct scan (ldct) for lung cancer screening	<1%	43	$6K
75565		<1%	549	$6K
84182		<1%	358	$6K
J1756	Injection, iron sucrose, 1 mg	<1%	80	$6K
73718		<1%	31	$6K
76514		<1%	562	$6K
29916		<1%	13	$6K
82150		<1%	1,010	$6K
88342		<1%	2,391	$6K
80178		<1%	383	$6K
82172		<1%	362	$6K
87350		<1%	333	$5K
92225		<1%	262	$5K
93880		<1%	89	$5K
12011		<1%	31	$5K
85045		<1%	1,828	$5K
86037		<1%	351	$5K
81050		<1%	614	$5K
82950		<1%	896	$5K
73702		<1%	15	$5K
86301		<1%	325	$5K
88173		<1%	965	$5K
73723		<1%	12	$5K
87449		<1%	1,230	$5K
J3475	Injection, magnesium sulfate, per 500 mg	<1%	3,424	$5K
86735		<1%	219	$5K
86231		<1%	271	$5K
G0008	Administration of influenza virus vaccine	<1%	1,252	$5K
64445		<1%	23	$5K
84446		<1%	527	$4K
G0257	Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility	<1%	409	$4K
J2543	Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)	<1%	1,103	$4K
86258		<1%	374	$4K
74181		<1%	17	$4K
11981		<1%	21	$4K
29823		<1%	63	$4K
95908		<1%	208	$4K
82436		<1%	823	$4K
83498		<1%	241	$4K
74019		<1%	200	$4K
86304		<1%	239	$4K
72193		<1%	13	$4K
89051		<1%	852	$4K
84300		<1%	1,122	$4K
87206		<1%	1,296	$4K
76937		<1%	401	$4K
J1611	Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg	<1%	63	$4K
J3370	Injection, vancomycin hcl, 500 mg	<1%	3,306	$4K
87116		<1%	1,295	$4K
82610		<1%	366	$4K
73223		<1%	13	$3K
82523		<1%	343	$3K
76821		<1%	45	$3K
85613		<1%	830	$3K
84145		<1%	980	$3K
0346T		<1%	33	$3K
87075		<1%	1,073	$3K
80169		<1%	144	$3K
G0390	Trauma response team associated with hospital critical care service	<1%	598	$3K
87102		<1%	1,353	$3K
72192		<1%	19	$3K
85670		<1%	688	$3K
82024		<1%	128	$3K
84155		<1%	590	$3K
51702		<1%	295	$3K
88313		<1%	1,303	$3K
J2270	Injection, morphine sulfate, up to 10 mg	<1%	4,220	$3K
00142		<1%	2,789	$3K
82085		<1%	225	$3K
J8501	Aprepitant, oral, 5 mg	<1%	213	$3K
80177		<1%	410	$3K
82010		<1%	1,093	$3K
J2310	Injection, naloxone hydrochloride, per 1 mg	<1%	270	$3K
M0239	Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring	<1%	37	$3K
80158		<1%	211	$3K
82652		<1%	279	$3K
88365		<1%	37	$3K
87109		<1%	138	$3K
86905		<1%	140	$2K
86335		<1%	43	$2K
84133		<1%	860	$2K
84478		<1%	439	$2K
76881		<1%	16	$2K
76825		<1%	12	$2K
J2704	Injection, propofol, 10 mg	<1%	33,104	$2K
95992		<1%	24	$2K
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	14,553	$2K
92610		<1%	79	$2K
97014		<1%	26	$2K
95819		<1%	15	$2K
80348		<1%	873	$2K
87653		<1%	185	$2K
00811		<1%	956	$2K
J0171	Injection, adrenalin, epinephrine, 0.1 mg	<1%	4,003	$2K
86618		<1%	217	$2K
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	4,299	$2K
81256		<1%	15	$2K
83935		<1%	645	$2K
81382		<1%	93	$2K
80202		<1%	135	$2K
72220		<1%	35	$2K
92060		<1%	17	$2K
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	13,070	$2K
85384		<1%	634	$2K
J1953	Injection, levetiracetam, 10 mg	<1%	436	$2K
64488		<1%	13	$2K
H2020	Therapeutic behavioral services, per diem	<1%	47	$2K
J0780	Injection, prochlorperazine, up to 10 mg	<1%	3,625	$2K
83090		<1%	341	$2K
83930		<1%	809	$2K
72083		<1%	26	$2K
00840		<1%	675	$2K
J1644	Injection, heparin sodium, per 1000 units	<1%	4,916	$2K
86308		<1%	278	$2K
86828		<1%	43	$2K
J3411	Injection, thiamine hcl, 100 mg	<1%	824	$2K
M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	<1%	12	$2K
86337		<1%	76	$2K
J0692	Injection, cefepime hydrochloride, 500 mg	<1%	1,121	$2K
0753T		<1%	1,725	$2K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	71	$2K
84432		<1%	70	$2K
76942		<1%	1,198	$2K
81596		<1%	26	$2K
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	22,085	$2K
J0295	Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm	<1%	1,917	$2K
84295		<1%	2,015	$2K
76827		<1%	13	$2K
88304		<1%	1,006	$2K
31629		<1%	17	$1K
00400		<1%	366	$1K
80179		<1%	962	$1K
80195		<1%	152	$1K
82239		<1%	92	$1K
J0689	Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg	<1%	6,753	$1K
00170	Anesthesia for intraoral procedures, including biopsy	<1%	279	$1K
C2625	Stent, non-coronary, temporary, with delivery system	<1%	648	$1K
00537		<1%	18	$1K
31628		<1%	20	$1K
G0237	Therapeutic procedures to increase strength or endurance of respiratory muscles, face to face, one on one, each 15 minutes (includes monitoring)	<1%	29	$1K
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	21,529	$1K
01922		<1%	13	$1K
99152		<1%	403	$1K
80299		<1%	136	$1K
29826		<1%	17	$1K
00790		<1%	349	$1K
85732		<1%	334	$1K
J0330	Injection, succinylcholine chloride, up to 20 mg	<1%	2,983	$1K
C1713	Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	<1%	2,715	$1K
87385		<1%	109	$1K
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	26,326	$1K
Q0162	Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	<1%	4,963	$1K
93356		<1%	129	$1K
J1250	Injection, dobutamine hydrochloride, per 250 mg	<1%	316	$1K
V2632	Posterior chamber intraocular lens	<1%	174	$1K
82378		<1%	120	$1K
90656		<1%	101	$1K
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	23,884	$1K
80321		<1%	56	$1K
80175		<1%	118	$1K
J2550	Injection, promethazine hcl, up to 50 mg	<1%	1,608	$998.46
01810		<1%	1,208	$994.51
C1781	Mesh (implantable)	<1%	267	$972.97
77002		<1%	145	$958.38
82542		<1%	70	$947.09
J0360	Injection, hydralazine hcl, up to 20 mg	<1%	1,081	$918.51
C9113	Injection, pantoprazole sodium, per vial	<1%	324	$902.12
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	2,894	$895.84
70355		<1%	53	$866.11
J0736	Injection, clindamycin phosphate, 300 mg	<1%	471	$861.38
00300		<1%	496	$856.69
J2001	Injection, lidocaine hcl for intravenous infusion, 10 mg	<1%	5,029	$847.57
C1769	Guide wire	<1%	2,936	$823.08
J2371	Injection, phenylephrine hydrochloride, 20 micrograms	<1%	3,257	$818.76
00520		<1%	332	$778.36
00145		<1%	464	$754.77
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	6,000	$754.74
84445		<1%	32	$708.98
90678		<1%	101	$703.70
20561		<1%	20	$678.42
01400		<1%	553	$670.54
99153	Mod sedat endo service >5yrs	<1%	301	$656.22
84080		<1%	59	$637.08
89060		<1%	106	$632.37
84255		<1%	55	$613.00
92609		<1%	14	$590.87
87535		<1%	13	$563.40
00120		<1%	54	$549.54
82810		<1%	833	$548.83
70250		<1%	51	$546.55
83835		<1%	30	$541.86
J1790	Injection, droperidol, up to 5 mg	<1%	2,044	$514.74
90472	Immunization administration, each additional vaccine (list separately)	<1%	128	$495.59
J2060	Injection, lorazepam, 2 mg	<1%	2,118	$495.41
64636		<1%	90	$490.08
C1894	Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	<1%	2,314	$472.50
93352		<1%	44	$469.94
J2919	Injection, methylprednisolone sodium succinate, 5 mg	<1%	1,008	$458.61
83695		<1%	50	$446.66
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	2,117	$442.47
Q0247	Injection, sotrovimab, 500 mg	<1%	87	$436.40
85549		<1%	66	$435.33
00732		<1%	510	$433.80
82805		<1%	455	$430.72
00320		<1%	154	$414.08
J3480	Injection, potassium chloride, per 2 meq	<1%	1,135	$408.97
C1725	Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability)	<1%	278	$408.00
77012		<1%	89	$400.40
86363		<1%	49	$399.71
90662		<1%	35	$390.05
00812		<1%	131	$384.00
86777		<1%	41	$383.46
A9500	Technetium tc-99m sestamibi, diagnostic, per study dose	<1%	755	$378.40
73565		<1%	12	$376.23
J0690	Injection, cefazolin sodium, 500 mg	<1%	2,974	$375.28
85240		<1%	19	$360.23
J1630	Injection, haloperidol, up to 5 mg	<1%	3,136	$336.00
J2920	Injection, methylprednisolone sodium succinate, up to 40 mg	<1%	414	$335.66
J1940	Injection, furosemide, up to 20 mg	<1%	1,351	$333.23
J2795	Injection, ropivacaine hydrochloride, 1 mg	<1%	3,462	$332.43
J2765	Injection, metoclopramide hcl, up to 10 mg	<1%	1,526	$314.93
80159		<1%	16	$307.07
86053		<1%	41	$301.40
82375		<1%	495	$298.56
J1580	Injection, garamycin, gentamicin, up to 80 mg	<1%	303	$287.20
82945		<1%	462	$286.50
01830		<1%	404	$274.77
J2598	Injection, vasopressin, 1 unit	<1%	422	$262.81
82657		<1%	16	$259.41
80156		<1%	13	$242.63
88108		<1%	44	$241.25
82787		<1%	27	$233.84
J0702	Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg	<1%	15	$229.48
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	<1%	5,136	$226.72
76510		<1%	14	$226.70
82365		<1%	93	$224.77
84540		<1%	51	$191.85
36416		<1%	3,393	$188.41
36591		<1%	20	$187.34
G8982	Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	<1%	176	$186.33
G0475	Hiv antigen/antibody, combination assay, screening	<1%	537	$182.84
46600		<1%	139	$177.25
84157		<1%	458	$176.06
84252		<1%	14	$170.71
G8979	Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	<1%	337	$160.81
J0456	Injection, azithromycin, 500 mg	<1%	437	$159.89
J8540	Dexamethasone, oral, 0.25 mg	<1%	583	$152.75
C1729	Catheter, drainage	<1%	403	$151.44
86692		<1%	18	$151.17
J2710	Injection, neostigmine methylsulfate, up to 0.5 mg	<1%	1,545	$146.35
J2785	Injection, regadenoson, 0.1 mg	<1%	140	$144.36
86645		<1%	17	$143.23
G8978	Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals	<1%	299	$139.37
G8981	Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals	<1%	142	$137.96
83518		<1%	17	$132.09
J2470	Injection, pantoprazole sodium, 40 mg	<1%	228	$128.84
85300		<1%	30	$120.60
83050		<1%	480	$114.48
95907		<1%	429	$108.44
J0461	Injection, atropine sulfate, 0.01 mg	<1%	88	$107.07
0752T		<1%	165	$103.90
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	447	$103.55
J1805	Injection, esmolol hydrochloride, 10 mg	<1%	571	$102.71
77001		<1%	79	$97.02
J1171	Injection, hydromorphone, 0.1 mg	<1%	972	$95.52
J1596	Injection, glycopyrrolate, 0.1 mg	<1%	1,138	$94.99
J0665	Injection, bupivicaine, not otherwise specified, 0.5 mg	<1%	2,021	$94.84
A9575	Injection, gadoterate meglumine, 0.1 ml	<1%	4,956	$91.01
J3489	Injection, zoledronic acid, 1 mg	<1%	19	$80.16
J1030	Injection, methylprednisolone acetate, 40 mg	<1%	441	$75.99
88300		<1%	15	$74.50
G1004	Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program	<1%	1,256	$73.50
J0737	Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg	<1%	112	$72.67
J2370	Injection, phenylephrine hcl, up to 1 ml	<1%	372	$72.23
97164		<1%	15	$69.39
J1836	Injection, metronidazole, 10 mg	<1%	317	$67.10
J0744	Injection, ciprofloxacin for intravenous infusion, 200 mg	<1%	425	$66.07
84436		<1%	13	$61.72
J7120	Ringers lactate infusion, up to 1000 cc	<1%	509	$59.30
88312		<1%	60	$53.66
J2003	Injection, lidocaine hydrochloride, 1 mg	<1%	1,292	$52.21
J0688	Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg	<1%	463	$46.91
J1920	Injection, labetalol hydrochloride, 5 mg	<1%	939	$46.58
88311		<1%	15	$39.03
A9573	Injection, gadopiclenol, 1 ml	<1%	2,910	$38.26
J3360	Injection, diazepam, up to 5 mg	<1%	35	$36.93
Q9957	Injection, perflutren lipid microspheres, per ml	<1%	875	$36.00
Q0164	Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	<1%	719	$32.47
J1642	Injection, heparin sodium, (heparin lock flush), per 10 units	<1%	1,136	$31.73
0754T		<1%	195	$28.84
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	102	$23.20
J3260	Injection, tobramycin sulfate, up to 80 mg	<1%	20	$23.14
87210		<1%	12	$20.87
A9585	Injection, gadobutrol, 0.1 ml	<1%	521	$18.24
J7507	Tacrolimus, immediate release, oral, 1 mg	<1%	196	$18.21
J2720	Injection, protamine sulfate, per 10 mg	<1%	19	$17.96
G8980	Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting	<1%	16	$16.89
J1040	Injection, methylprednisolone acetate, 80 mg	<1%	224	$13.49
J0173	Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg	<1%	372	$13.20
J7517	Mycophenolate mofetil, oral, 250 mg	<1%	66	$8.66
Q0169	Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	<1%	423	$4.86
74328		<1%	245	$4.36
87305		<1%	26	$4.06
J2004	Injection, lidocaine hcl with epinephrine, 1 mg	<1%	21	$3.75
Q0243	Injection, casirivimab and imdevimab, 2400 mg	<1%	119	$1.04
J0612	Injection, calcium gluconate, not otherwise specified, 10 mg	<1%	50	$0.78
Q0244	Injection, casirivimab and imdevimab, 1200 mg	<1%	75	$0.67
Q0239	Injection, bamlanivimab-xxxx, 700 mg	<1%	14	$0.14
Q0245	Injection, bamlanivimab and etesevimab, 2100 mg	<1%	12	$0.06
00910		0%	191	$0.00
00918		0%	153	$0.00
M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	0%	69	$0.00
00402		0%	140	$0.00
C1887	Catheter, guiding (may include infusion/perfusion capability)	0%	794	$0.00
00140		0%	168	$0.00
C1760	Closure device, vascular (implantable/insertable)	0%	250	$0.00
01630		0%	274	$0.00
01202		0%	12	$0.00
A9541	Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries	0%	500	$0.00
01402		0%	34	$0.00
C1874	Stent, coated/covered, with delivery system	0%	31	$0.00
Q9966	Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	0%	108	$0.00
C1762	Connective tissue, human (includes fascia lata)	0%	60	$0.00
C1751	Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis)	0%	56	$0.00
76376		0%	29	$0.00
88302		0%	90	$0.00
A9537	Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries	0%	13	$0.00
C1730	Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes)	0%	269	$0.00
00902		0%	60	$0.00
C1726	Catheter, balloon dilatation, non-vascular	0%	946	$0.00
76377		0%	898	$0.00
01214		0%	82	$0.00
00813		0%	450	$0.00
01480		0%	224	$0.00
C1889	Implantable/insertable device, not otherwise classified	0%	16	$0.00
J1010	Injection, methylprednisolone acetate, 1 mg	0%	236	$0.00
A9503	Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries	0%	89	$0.00
J1720	Injection, hydrocortisone sodium succinate, up to 100 mg	0%	19	$0.00
00160		0%	56	$0.00
80349		0%	15	$0.00
36226		0%	36	$0.00
C1778	Lead, neurostimulator (implantable)	0%	14	$0.00
73501		0%	29	$0.00
00952		0%	14	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialPYLES, BRYAN (ASSOCIATE VICE PRESIDENT OF FINANCE)

Same official

Other billing entities under PYLES, BRYAN

Full network →

Provider	Location	Paid
Osu Wexner Medical Center Ambulatory Surgery Center	Westerville, OH	$907K
Osu Wexner Medical Center Ambulatory Surgery Center	Dublin, OH	$241K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.